advanced chronic renal insufficiency
Conditions
Brief summary
Primary endpoint: Presence of CMV infection or disease after renal transplantation. This variable will be evaluated at 6 months post-transplantation.
Detailed description
Recipient demographic variables: gender and age, Recipient variables related to chronic kidney disease (CKD): etiology of CKD, renal replacement therapy (RRT) prior to transplantation, time on RRT in months., Donor variables: demographics (age and sex), cause of death, donor type (living, cadaveric and cadaveric donor type), Ig G CMV serology., Peri-transplant variables, CMV-related variables
Interventions
DRUGValganciclovir Aurovitas 450 mg comprimidos recubiertos con película EFG
DRUGUrbason 40 mg polvo y disolvente para solución inyectable
DRUGprednisona cinfa 5 mg comprimidos EFG
DRUGMyfortic 180 mg comprimidos gastrorresistentes.
Sponsors
Hospital Universitario La Paz
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: Presence of CMV infection or disease after renal transplantation. This variable will be evaluated at 6 months post-transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recipient demographic variables: gender and age, Recipient variables related to chronic kidney disease (CKD): etiology of CKD, renal replacement therapy (RRT) prior to transplantation, time on RRT in months., Donor variables: demographics (age and sex), cause of death, donor type (living, cadaveric and cadaveric donor type), Ig G CMV serology., Peri-transplant variables, CMV-related variables | — |
Countries
Spain
Outcome results
None listed